Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

DSpace Repository

Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Author: Weisel, Katja; Dimopoulos, Meletios; Moreau, Philippe; Yagci, Munci; Larocca, Alessandra; Kanate, Abraham S.; Vural, Filiz; Cascavilla, Nicola; Basu, Supratik; Johnson, Peter; Byeff, Peter; Hus, Marek; Rodriguez-Otero, Paula; Muelduer, Ercan; Anttila, Pekka; Hayden, Patrick J.; Krauth, Maria-Theresa; Lucio, Paulo; Ben-Yehuda, Dina; Mendeleeva, Larisa; Guo, Shien; Yu, Xin; Grote, Lara; Biyukov, Tsvetan; Dhanasiri, Sujith; Richardson, Paul
Tübinger Autor(en):
Weisel, Katja
Published in: Leukemia & Lymphoma (2020), Bd. 61, H. 8, S. 1850-1859
Verlagsangabe: Taylor & Francis Ltd
Language: English
Full text: http://dx.doi.org/10.1080/10428194.2020.1747066
ISSN: 1029-2403
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)